ClinicalTrials.gg
RecruitingNCT06118307Updated Nov 7, 2023

Shanghai Ovarian Cancer and Family Care Project

An observational study in Ovarian Cancer, sponsored by Shanghai First Maternity and Infant Hospital. Recruiting at 1 site in China. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-07.

Sponsored by Shanghai First Maternity and Infant Hospital · Observational

How we know

From the registry’s dates

  • Started Jan 2013; still recruiting 13 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
3,546
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 395 studies in Ovarian Neoplasms with a site in China — 201 open to participants now, 233 under way, 36 of them phase 3. Ovarian Neoplasms · China.

Planned enrollment
6th of 73
3,546 · median 200
Started
2013
with 6 others
Observational
73 of 395
36 open now
Primary completion
2028-10
later than 195 of 232 live
Registered
226th of 395
by date

Among the 395 studies in Ovarian Neoplasms with a site in China, this one is the 6th largest by planned enrollment of the 73 observational ones that give a count, is one of 7 that started in 2013, is one of 73 observational ones, reaches primary completion later than 195 of the 232 other live ones, and was the 226th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

201 of the 395 studies in Ovarian Neoplasms with a site in China are open now. Recruiting first, the newest first:

196 more — sign in →

All 201 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 395 studies in Ovarian Neoplasms with a site in China, or all of them as a file.
02

Study summary

Ovarian cancer is the most lethal gynaecological malignancy, but its incidence in the general population is low. Due to the lack of effective prevention and successful screening approaches, most cases are diagnosed at advanced stages, leading to poor prognosis. In order to address the research requirements pertaining to ovarian cancer, the Shanghai Ovarian Cancer and Family Care Project was established. This initiative offers hospital-based resources for investigating ovarian cancer and high-risk populations. The project comprises an on-going ovarian cancer cohort, a high-risk population cohort, and a healthy population cohort. By leveraging these comprehensive cohorts, the project provides a unique platform for in-depth studies on the detection, prevention, early diagnosis, treatment, and prognosis of ovarian cancer.

03

Conditions studied

  • Ovarian Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients attending the oncology department; patients with known risk factors for ovarian cancer; healthy individuals who are in good health determined by physical examination.

Eligibility criteria

Participant meet the criteria for one of the following conditions:

  • Patients attending the oncology department require differential diagnosis of ovarian cancer.
  • Patients with known high-risk factors for ovarian cancer, such as history of ovarian cancer or BRCA-associated cancer, etc.
  • Patients attending the Physical Examination Center who have normal findings on physical examination and no symptoms.

Exclusion Criteria:

  • Individuals with evidence of another active cancer.
  • Individuals who have prior bilateral oophorectomy.
  • Individuals who are unwilling or unable to sign the form.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
3,546 participants (estimated)
Patient registry
No

Groups and cohorts

  • Ambispective patient cohort

    Patients attending the oncology department require differential diagnosis of ovarian cancer.

  • High-risk population cohort

    Family members of ovarian cancer patients; family history of BRCA mutation-related disease; abnormal findings on ovarian cancer screening; history of ovarian disease and other risk factors.

  • Healthy control cohort

    Healthy women with normal health examination results.

06

What researchers measure

Primary outcomes

  1. Death due to ovarian cancer

    Death due to ovarian cancer determined by independent outcomes committee.

    Time frame: From diagnosis of ovarian cancer until October 31, 2028.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2013 (actual). Primary completion is estimated for Oct 2028, 189 months after the start.

Of 216 non-industry observational studies under Ovarian Neoplasms, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 206. This study's planned 189 months is above that.

Counting every sponsor, half of 268 studies reached it within 61 months; a quarter within 35 and three quarters within 185.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2023
First posted
Nov 7, 2023
StartActual
Jan 1, 2013
Primary completionEst.
Oct 13, 2028
CompletionEst.
Oct 13, 2028
Last update
Nov 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06118307
Lead sponsor
Shanghai First Maternity and Infant Hospital
Responsible party
Sponsor
First posted
Nov 7, 2023
Start date
Jan 1, 2013
Primary completion
Oct 13, 2028 (estimated)
Completion
Oct 13, 2028 (estimated)
Last update
Nov 7, 2023

Study contacts

Yu Wang, MD; PhD
Contact
renjiwangyu@126.com
20261208 ext. 86

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion